Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
This study is ongoing, but not recruiting participants.
Study NCT00019786 Information provided by National Cancer Institute (NCI)
First Received: July 11, 2001 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Colorectal Cancer
Islet Cell Tumor
Liver Cancer
Metastatic Cancer
Neuroendocrine Carcinoma
Additional conditions recognized in this trial
Adenoma, Islet Cell
Carcinoma
Carcinoma, Neuroendocrine
Colorectal Neoplasms
Liver Neoplasms
Neoplasm Metastasis
More general conditions related to this trial
Adenocarcinoma
Adenoma
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplastic Processes
Neuroectodermal Tumors
Neuroendocrine Tumors
Pancreatic Diseases
Pancreatic Neoplasms
Pathologic Processes
Rectal Diseases
Interventions listed in this trial
isolated perfusion
melphalan
conventional surgery
More general drug interventions related to this trial
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)
Back to top of Main Content
